The U.S. Food and Drug Administration approved bremelanotide subcutaneous injection under the brand name Vyleesi on June 21, 2019. This approval authorizes one specific indication: acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. No nasal spray formulation of bremelanotide or PT-141 holds FDA approval.
Compounded nasal preparations occupy a separate legal category governed by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. They do not fall under the new drug application that authorized Vyleesi.
This regulatory divergence carries direct consequences for prescribers, pharmacies, and patients. The approved injection carries labeling derived from clinical trial data submitted to the FDA. Compounded nasal sprays carry no such agency-reviewed labeling. Their legality rests on compliance with compounding statutes and enforcement discretion rather than any demonstration of safety or efficacy specific to intranasal delivery.
The Statutory Baseline: What the 2019 Approval Covers
Bremelanotide is a synthetic peptide that activates melanocortin receptors in the central nervous system. The FDA's 2019 approval recognized Vyleesi as a treatment for HSDD in premenopausal women based on clinical trial evidence submitted through the standard new drug application pathway. Rite Aid notes that this approval made bremelanotide "one of the few peptides in this category with a defined, approved clinical indication" (Rite Aid).
The approval did not extend to men, postmenopausal women, or any route of administration other than subcutaneous injection. It did not establish efficacy for nasal absorption, transmucosal bioavailability, or compounded delivery systems. When telehealth providers describe compounded PT-141 nasal spray as FDA-approved, that characterization misstates the regulatory record. The approved product is an injection. The nasal spray is a compounded drug.
Where Compounded Nasal Formulations Fit
Compounded PT-141 nasal sprays are produced by pharmacies operating under section 503A or registered outsourcing facilities operating under section 503B. A PeptideDeck guide describes telehealth platforms prescribing compounded nasal spray and injectable forms to both men and women off-label, typically at $80 to $200 per month (PeptideDeck). Those prescriptions do not run through the Vyleesi approval channel. They operate solely within the compounding framework.
Section 503A pharmacies compound for individual patients pursuant to a prescription and face strict limits on interstate distribution. Section 503B outsourcing facilities may distribute across state lines but must adhere to current good manufacturing practice standards. Facilities that exceed statutory thresholds or compound preparations deemed essentially a copy of an approved product risk enforcement action.
The compliance question for any compounded PT-141 nasal spray is not whether the FDA reviewed the formulation. The question is whether the producing facility holds the correct registration and operates within statutory boundaries.
Evidence Gaps Regarding Intranasal Delivery
Clinical trial evidence supporting bremelanotide derives exclusively from studies of subcutaneous injection. A comparison of delivery routes published by BeyondMD reports that both injection and nasal spray typically begin working within 30 to 60 minutes in clinical use (BeyondMD). The source notes that injection absorption is more predictable because it bypasses variables such as nasal mucosa condition and administration technique.
BeyondMD observes that injections tend to produce longer-lasting responses while nasal sprays may offer a shorter window of effect. This is a practical observation from a telehealth provider rather than a finding from a controlled bioequivalence study. The supplied records contain no head-to-head pharmacokinetic data comparing intranasal bremelanotide with the approved subcutaneous route.
No prescriber can cite an agency-reviewed document establishing that a given nasal formulation delivers a predictable dose to the systemic circulation. Compounding pharmacies and telehealth vendors describe nasal sprays with varying concentrations. One pharmacy lists a 5 mg/mL formulation (PHC Pharmacy). Another vendor describes a 1 mg per spray product (Peaks Curative). AgeMD explicitly states in its structured product data that PT-141 nasal spray is "Not FDA-approved" (AgeMD).
These are separate compounded preparations with no common labeling standard or established bioequivalence.
Liability Distinctions for Prescribers
A clinician prescribing Vyleesi operates within an FDA-approved indication and labeling framework. A clinician prescribing compounded PT-141 nasal spray for a man, a postmenopausal woman, or any off-label use assumes a different liability profile. The compounded product has not been reviewed by the FDA for safety or efficacy. The prescriber carries sole responsibility for dose selection, route justification, and adverse event monitoring.
The pt 141 bremelanotide clinical pharmacology guide covers the mechanism and trial evidence for the approved injection. Readers evaluating compounded nasal options must separate that evidence base from the regulatory status of the spray itself.
Compounded nasal sprays also intersect with broader peptide supply chain compliance. The same 503B registration and statutory threshold framework governs other compounded peptides, including lipolytic peptides aod 9604 pt 141. This framework applies equally to formulations marketed alongside products such as glow peptide, klow peptide, and glp 1 peptides. Compounding status does not function as a shortcut around new drug approval. Enforcement discretion is conditional and revocable.
Compliance Verification for Patients and Providers
Patients receiving compounded PT-141 nasal spray should verify three regulatory facts. First, confirm whether the producing pharmacy is a registered 503B outsourcing facility or a state-licensed 503A pharmacy and whether the prescription falls within relevant statutory limits. Second, determine the specific concentration and dose delivered per spray and identify the authority that established that dosing regimen.
Third, ask what evidence the prescriber cites for expecting nasal delivery to approximate the approved injection's effect absent public bioequivalence data.
Compounded PT-141 nasal spray is not per se unlawful. Its legality depends entirely on facility registration and statutory compliance rather than nasal-specific approval. Representing a nasal spray as FDA-approved conflates the 2019 injection approval with a compounded product that has never undergone equivalent review. This distinction determines which agency records exist, which labeling applies, and where liability rests following an adverse event.
